ProfileGDS5678 / 1417985_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 86% 87% 85% 73% 75% 73% 67% 84% 87% 86% 87% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7315288
GSM967853U87-EV human glioblastoma xenograft - Control 26.7810987
GSM967854U87-EV human glioblastoma xenograft - Control 36.4696186
GSM967855U87-EV human glioblastoma xenograft - Control 46.8404587
GSM967856U87-EV human glioblastoma xenograft - Control 56.4065585
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6833773
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.846975
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6449373
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1179167
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1894384
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.722787
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.630186
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6523987
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6667587